Predict the therapeutic effect of your ADC
Traditional preclinical models like cell lines and PDXs often fall short in predicting real-world ADC performance—leading to costly clinical failures. HUB Organoids® offer a smarter solution.
In this AACR 2025 proof-of-concept study, we used a basket of 239 PDOs—spanning 12 tumor types—to evaluate the efficacy, potency, and specificity of the FDA-approved ADC Tisotumab Vedotin (Tivdak), which targets Tissue Factor (F3).
What you’ll learn from this poster:
- Why PDOs are uniquely suited to evaluate ADC response, target expression, and specificity
- How Tivdak performed across a range of tumor-derived PDOs Our approach to measuring antigen expression via OrganoID-Flow and linking it to ADC efficacy
- The structure and depth of our organoid catalog—including clinical metadata, RNAseq, and DNAseq
Want to test your ADC efficacy before entering the clinic?
Make go/no-go decisions with confidence – backed by data that translates
